Stock listing

NASDAQ:MGTX MeiraGTx Holdings plc Stock

Home listing (NASDAQ) of MeiraGTx Holdings plc

Follow MeiraGTx Holdings plc into a list and get an email when it puts out news.

Share price · NASDAQ:MGTX

$7.98 USD -0.34 (-4.1%)

Close on Nov 20, 2026

Past year +7.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$7.81 – $8.23 USDNov 20, 2026
Volume
1.01M sharesNov 20, 2026
Market cap
$766.4M USDAt the close on Nov 20, 2026 · price × 96.04M shares outstanding
52-week range
$6.62 – $15.35 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$9.34M USDMedian day 755,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
MeiraGTx Holdings plc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:MGTX · Home$7.98 USD-0.34 (-4.1%)1,013,977$7.97$8.23$7.81$8.32Close on Nov 20, 2026
Frankfurt:328€7.15 EUR-0.25 (-3.4%)—€7.30€7.30€7.15€7.40Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MGTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$7.98-0.34-4.1%$7.97$8.23$7.811,013,977
$8.32-0.14-1.7%$8.40$8.64$8.31584,565
$8.46-0.28-3.2%$8.70$8.70$8.251825,035
$8.74-0.44-4.8%$9.15$9.26$8.70706,057
$9.18+0.39+4.4%$8.80$9.28$8.60731,921
$8.79-0.89-9.2%$9.13$9.39$8.771,362,621
$9.68+0.06+0.6%$9.70$9.76$9.53455,889
$9.62+0.13+1.4%$9.30$9.70$9.30774,741
$9.49+0.49+5.4%$9.13$9.54$8.95544,741
$9.00+0.49+5.8%$8.44$9.12$8.44703,329
$8.51-0.91-9.7%$9.325$9.38$8.47686,674
$9.42-0.10-1.1%$9.81$9.92$9.39597,709
$9.52+0.20+2.1%$9.36$9.52$9.31393,365
$9.32-0.17-1.8%$9.50$9.521$9.20580,103
$9.49-0.215-2.2%$9.65$9.70$9.30452,176
$9.705-0.045-0.5%$9.79$9.895$9.54499,163
$9.75+0.35+3.7%$9.28$9.765$9.15633,144
$9.40+0.22+2.4%$9.20$9.58$9.11722,942
$9.18-0.03-0.3%$9.24$9.33$9.05648,655
$9.21-0.56-5.7%$9.70$9.72$9.08595,500
$9.77-0.09-0.9%$9.80$10.06$9.67471,900
$9.86-0.11-1.1%$9.97$10.23$9.835635,600
$9.97+0.52+5.5%$9.45$10.11$9.405755,900
$9.45+0.17+1.8%$9.48$9.73$9.29759,500
$9.28-0.61-6.2%$9.89$9.89$9.245666,400
$9.89+0.48+5.1%$9.42$9.93$9.38836,400
$9.41-0.53-5.3%$9.82$10.01$9.361,104,100
$9.94-0.44-4.2%$10.26$10.40$9.861,122,100
$10.38-0.31-2.9%$10.69$10.76$10.32506,500
$10.69+0.19+1.8%$10.52$10.99$10.48523,400
$10.50-0.32-3.0%$10.70$10.72$10.36830,400
$10.82+0.22+2.1%$10.50$11.01$10.322,310,000
$10.60-0.32-2.9%$10.93$10.95$10.53944,400
$10.92+0.13+1.2%$10.77$11.03$10.59941,600
$10.79+0.13+1.2%$10.75$11.00$10.66820,000
$10.66-0.34-3.1%$11.36$11.36$10.541,066,000
$11.00-0.13-1.2%$11.19$11.60$10.971,423,800
$11.13+0.02+0.2%$11.02$11.17$10.87875,900
$11.11+0.20+1.8%$10.79$11.27$10.59930,000
$10.91-0.14-1.3%$10.90$11.28$10.681,555,600
$11.05-0.70-6.0%$11.42$11.56$11.001,605,300
$11.75-0.60-4.9%$12.26$12.50$11.461,419,200
$12.35-0.73-5.6%$13.16$13.24$12.181,439,300
$13.08-0.17-1.3%$13.47$13.47$12.801,286,200
$13.25+0.20+1.5%$12.92$13.34$12.92941,200
$13.05+0.29+2.3%$13.21$13.34$12.91953,000
$12.760.000.0%$12.79$12.95$12.63917,300
$12.76-0.12-0.9%$12.88$12.89$12.501,025,600
$12.88+0.09+0.7%$12.81$13.22$12.76492,300
$12.79-0.06-0.5%$13.04$13.14$12.75459,500
$12.85-0.41-3.1%$13.02$13.16$12.65715,200
$13.26-0.27-2.0%$13.40$13.76$13.25534,400
$13.53-0.36-2.6%$13.54$13.72$13.22611,400
$13.89-0.08-0.6%$13.70$14.05$13.60531,100
$13.97-0.09-0.6%$14.01$14.15$13.76824,100
$14.06-0.13-0.9%$14.48$14.73$13.72629,400
$14.19+0.38+2.8%$13.66$14.60$13.66880,400
$13.81-0.01-0.1%$13.90$14.14$13.39715,700
$13.82-0.32-2.3%$13.93$14.09$13.65914,200
$14.14-0.42-2.9%$14.46$14.58$14.121,013,600
$14.56-0.36-2.4%$14.85$14.92$14.41606,500
$14.92+0.09+0.6%$15.01$15.31$14.63689,608
$14.83+0.49+3.4%$14.28$14.94$13.72821,374
$14.34-0.20-1.4%$14.70$14.85$14.10635,500
$14.54-0.43-2.9%$14.93$15.01$14.50861,900
Ticker
NASDAQ:MGTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All MeiraGTx Holdings plc news

MeiraGTx Holdings plc on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 107 in all · newest Nov 16, 2026 · oldest 2019
Decks
12 decks · latest November 2026

Where MeiraGTx Holdings plc is listed

ListingExchangeCountryCurrency
NASDAQ:MGTX · Home listing · This pageNASDAQUnited StatesUSD
gettex:328gettexGermanyEUR
LS Exchange:A2JGHFLS ExchangeGermanyEUR
Lang & Schwarz:A2JGHFLang & SchwarzGermanyEUR
BOATS:MGTXBOATSUnited StatesUSD
Tradegate:328TradegateGermanyEUR
Frankfurt:328FrankfurtGermanyEUR
Munich:328MunichGermanyEUR
Stuttgart:328StuttgartGermanyEUR

Valuation

P/E 9.8× against a median of 4.4×: 4th lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$715.6M USD
P/E
9.8×
EV/sales
1.8×
EV/EBITDA
3.7×
Price/book
3.6×
Gross margin
83.7%
Operating margin
44.8%
Net margin
19.5%
Debt to equity
0.6×
Beta vs S&P 500
1.57

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
MeiraGTx Holdings plc · NASDAQ:MGTXUS$766.4MUS$715.6M9.8×1.8×3.7×3.6×19.5%0.6×1.57
Arbutus Biopharma Corporation · NASDAQ:ABUSUS$796.4MUS$458.9M3.6×2.5×3.1×9.3×121.2%0.0×1.10
Genfleet Therapeutics (Shanghai), Inc. Class H · HKEX:2595US$787.6MUS$518.9Mn/a26.5×n/a3.3×n/a0.0×n/a
Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335US$778.8MUS$599.7Mn/an/an/a5.5×n/a0.0×n/a
Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWDUS$778.1MUS$702.9M5.2×1.8×n/an/a37.4%n/a1.16
Syndax Pharmaceuticals, Inc. · NASDAQ:SNDXUS$772.7MUS$695.6Mn/a2.4×n/an/a−72.4%n/a0.64
ORIC Pharmaceuticals, Inc. · NASDAQ:ORICUS$764.9MUS$503.6Mn/an/an/a2.3×n/a0.0×1.22
Inventiva SA · EURONEXT:IVAUS$761.0MUS$577.4Mn/a117×n/a11.8×n/a1.1×n/a
Rigel Pharmaceuticals, Inc. · NASDAQ:RIGLUS$754.9MUS$663.4M2.5×2.3×8.3×1.7×106.6%0.0×1.02
Obsidian Therapeutics, Inc. · NASDAQ:OBXUS$741.3MUS$530.4M13.0×n/an/a2.3×n/a0.0×n/a
Monte Rosa Therapeutics, Inc. · NASDAQ:GLUEUS$738.3MUS$196.8Mn/a2.8×n/a1.5×−186.2%0.1×0.92
Median of the othersUS$768.8MUS$553.9M4.4×2.5×5.7×2.8×37.4%0.0×1.06

Forecasts

5 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
27.75 USD · Analysts' mean
EPS, year to Dec 2026
0.51 · 3 analysts
Revenue, year to Dec 2026
333.3M · 4 analysts

Team and board

Officers

OfficerRole
Alexandria ForbesBoard Member, President and Chief Executive Officer

Board

DirectorRole
Keith R. HarrisChairman of the Board
Alan SebulskyIndependent Board Member
Alexandria ForbesBoard Member, President and Chief Executive Officer
Debra YuIndependent Board Member
Ellen HukkelhovenBoard Member
Nicole SeligmanIndependent Board Member
Thomas E. ShenkIndependent Board Member

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−9.2%
Q2 2026Aug 13, 2026 · Before open−2.2%
Q1 2026May 14, 2026 · Before open−0.2%
Q4 2025Mar 12, 2026−5.4%
Q3 2025Nov 13, 2025 · Before open−4.6%
Q2 2025Aug 14, 2025 · Before open−0.1%
Q1 2025May 13, 2025 · Before open−8.4%
Q4 2024Mar 12, 2025 · Before open+5.1%
Q3 2024Nov 13, 2024 · Before open+5.7%
Q2 2024Aug 12, 2024 · Before open−8.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open−0.8%
Q4 2023Mar 14, 2024 · Before open−7.1%
Q3 2023Nov 14, 2023 · Before open+2.3%
Q2 2023Aug 10, 2023 · Before open+4.3%
Q1 2023May 11, 2023 · Before open−6.0%
Q4 2022Mar 14, 2023 · Before open+1.8%
Q3 2022Nov 10, 2022 · After close−3.7%
Q2 2022Aug 11, 2022 · Before open+6.7%
Q1 2022May 12, 2022 · Before open+0.3%
Q4 2021Mar 10, 2022 · Before open+0.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck106 slidesNovember 2026
Investor Presentation (October 2026)Investor deck24 slidesOctober 2026
Investor Presentation (October 2026)Investor deck97 slidesOctober 2026
Investor Presentation (October 2026)Investor deck13 slidesOctober 2026
Investor Presentation (August 2026)Investor deck97 slidesAugust 2026
Foundation Fighting Blindness (FFB) Retinal Therapeutics Innovation Summit 2025Conference14 slidesMay 2, 2025
Technical Presentation (April 2024)Technical16 slidesApril 2024
Technical Presentation (June 2023)Technical28 slidesJun 27, 2023
ARVO Annual Meeting 2023Conference10 slidesApril 2023
ARVO Annual Meeting 2022Conference13 slidesMay 4, 2022
All 12 decks
DeckKindSlidesDate
Technical Presentation (December 2021)Technical22 slidesDec 7, 2021
EURETINA Virtual Meeting 2021Conference9 slidesSep 12, 2021

Open Decks

Financings

RaiseDate
Public offering of ordinary shares
Announced: about US$100M · US$9 a share · BofA Securities +2
Dealers: BofA Securities (co-lead), Goldman Sachs & Co. LLC (co-lead), Raymond James
Use of proceeds: Fund operating expenses and capital expenditures, including potential commercial launches of bota-vec and AAV-hAQP1 if approved, into the second half of 2028
Apr 16, 2026
Strategic investment of minority stake in manufacturing subsidiary
Announced: strategic investment
Buyers: Hologen Limited (minority stake in MeiraGTx's manufacturing subsidiary)
Use of proceeds: Fund a portion of the annual funding of MeiraGTx's manufacturing subsidiary
Mar 13, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on Jun 7, 2018.

Price
US$15.00 a share
Shares offered
5,000,000 ordinary shares
Offering size
US$75 million
Underwriters' option
Up to 750,000 more shares
Underwriters
BofA Merrill Lynch, Barclays, Evercore ISI, Chardan · In the order on the cover
Shares delivered
On or about Jun 12, 2018

Steps

StepWhen
Draft sent to the SEC in confidenceMar 29, 2018
Filed publiclyMay 14, 2018
Amended 3 timesNewest Jun 4, 2018
Declared effective by the SECJun 7, 2018
Shares registered with an exchangeJun 8, 2018
Final prospectus, with the priceJun 8, 2018

Open IPO · From the cover of the final prospectus (424B4) filed Jun 8, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue81.4M33.3M14.0M15.9M37.7M15.6M13.3M000
Cost of revenue4.84M23.8M13.7M8.72M7.87M2.05M679.2K243.1K
Gross profit76.5M9.49M14.0M15.9M37.7M15.6M13.3M-2.05M-679.2K-243.1K
Research and development129.6M119.5M103.8M85.7M66.7M33.9M24.9M33.6M22.4M14.0M
Selling, general and administrative52.9M54.2M47.3M46.5M43.8M44.2M46.7M44.5M9.33M6.03M
Operating income-106.0M-164.2M-137.1M-116.4M-72.8M-62.6M-58.3M-78.1M-31.7M-20.1M
Depreciation and amortization12.5M12.8M13.7M8.72M7.87M4.17M2.24M2.05M679.2K243.1K
EBITDA-93.4M-151.4M-123.3M-107.6M-64.9M-58.4M-56.0M-76.1M-31.0M-19.8M
Interest expense12.2M13.3M13.2M4.95M288.0K139.0K48.6K33.4K42.9K25.4K
Income before tax-114.2M-147.8M-84.0M-129.6M-79.6M-58.0M-54.7M-83.3M-31.0M-19.8M
Income tax00013.3M000-474.4K0-280.4K
Net income-114.2M-147.8M-84.0M-129.6M-79.6M-58.0M-54.7M-82.9M-31.0M-19.5M
Earnings per share, basic-1.42-2.12-1.49-2.87-1.80-1.54-1.65-4.47-3.72-1.01
Earnings per share, diluted-1.42-2.12-1.49-2.87-1.80-1.54-1.65-4.47-3.72

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents65.9M103.7M129.6M115.5M137.7M209.5M227.2M68.1M8.55M17.5M
Receivables3.00M707.0K10.1M21.3M35.0M55.4M37.1M4.52M
Inventory0385.0K08.13M8.10M7.08M4.46M
Current assets91.8M123.5M159.6M154.3M183.2M272.6M269.0M74.7M11.5M19.1M
Property, plant and equipment105.5M102.9M115.9M109.3M75.9M44.0M23.9M22.0M14.3M2.81M
Total assets244.4M269.8M326.7M318.2M320.2M363.7M323.9M96.9M25.9M22.6M
Accounts payable10.1M23.6M16.0M16.6M15.3M7.13M3.76M3.04M7.06M1.47M
Current liabilities122.6M60.8M67.1M82.1M68.1M54.1M49.2M15.5M21.4M6.04M
Long-term debt49.7M73.2M72.1M71.3M953.0K34.0K5.00K
Total debt88.7M84.8M89.3M92.2M23.7M22.2M23.2M34.3K1.51M11.5K
Total liabilities250.2M201.9M188.6M200.5M134.8M125.1M133.1M15.8M21.9M39.7M
Shareholders' equity-5.79M67.8M138.2M117.7M185.4M238.6M190.8M81.1M-47.4M-17.1M
Shares outstanding81.1M78.4M63.6M48.5M44.5M44.2M36.8M27.4M8.71M19.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-46.4M-104.5M-105.4M-73.1M-10.5M-64.0M20.0M-58.9M-18.1M-14.4M
Capital spending-3.83M-4.96M-20.2M-45.0M-46.4M-20.9M-8.98M-11.3M-10.5M-2.59M
Free cash flow-50.2M-109.5M-125.5M-118.1M-56.9M-84.9M11.1M-70.1M-28.6M-17.0M
Cash from investing-4.11M23.5M34.0M-45.0M-61.7M-37.0M-9.37M-11.3M-10.5M-2.59M
Cash from financing12.3M54.5M84.0M95.2M1.71M82.7M148.2M130.0M19.3M20.8M
Dividends paid0-70.0M0
Share buybacks-1.52M-2.77M1.71M82.8M148.3M131.5M16.9M20.8M
Change in cash-38.2M-26.5M12.7M-22.9M-70.5M-18.3M158.9M59.9M-9.25M3.37M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 17, 2026Insider tradeSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
S-3ASR · Registration statementNov 12, 2026Offer documentSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
144 · Notice of proposed saleOct 20, 2026Other filingsSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
144 · Notice of proposed saleOct 6, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
8-K · Current reportSep 23, 2026Management or board changeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 13, 2026Offer documentSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
144 · Notice of proposed saleJul 21, 2026Other filingsSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
8-K · Current reportJul 7, 2026Material contractSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
8-K · Current reportJun 15, 2026Meeting outcomeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 14, 2026Insider tradeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
4/A · Change in ownership, amendedApr 28, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 24, 2026Big-stake noticeSEC
8-K · Current reportApr 24, 2026Material contractSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
144 · Notice of proposed saleApr 21, 2026Other filingsSEC
424B5 · ProspectusApr 16, 2026Offer documentSEC
8-K · Current reportApr 16, 2026Material contractSEC
8-K · Current reportApr 16, 2026Acquisition or disposalSEC
8-K · Current reportApr 16, 2026Current reportSEC
4 · Change in ownershipApr 7, 2026Insider tradeSEC
144 · Notice of proposed saleApr 7, 2026Other filingsSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
144 · Notice of proposed saleMar 24, 2026Other filingsSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 2, 2026Big-stake noticeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
8-K · Current reportJan 2, 2026Material contractSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
8-K · Current reportNov 10, 2025Material contractSEC
4 · Change in ownershipOct 21, 2025Insider tradeSEC
144 · Notice of proposed saleOct 21, 2025Other filingsSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
144 · Notice of proposed saleOct 7, 2025Other filingsSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
4 · Change in ownershipJul 22, 2025Insider tradeSEC
144 · Notice of proposed saleJul 22, 2025Other filingsSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
144 · Notice of proposed saleJul 8, 2025Other filingsSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
8-K · Current reportJun 26, 2025Current reportSEC
8-K · Current reportJun 17, 2025Meeting outcomeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
8-K · Current reportMay 9, 2025Current reportSEC
ARS · Annual report to shareholdersApr 30, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
4 · Change in ownershipApr 22, 2025Insider tradeSEC
144 · Notice of proposed saleApr 22, 2025Other filingsSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
144 · Notice of proposed saleApr 8, 2025Other filingsSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
8-K · Current reportApr 4, 2025Material contractSEC
S-8 · Registration statement for employee plansMar 13, 2025Offer documentSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
8-K · Current reportMar 13, 2025ResultsSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipJan 21, 2025Insider tradeSEC
144 · Notice of proposed saleJan 21, 2025Other filingsSEC
4 · Change in ownershipJan 16, 2025Insider tradeSEC
4 · Change in ownershipJan 16, 2025Insider tradeSEC
4 · Change in ownershipJan 16, 2025Insider tradeSEC
4 · Change in ownershipJan 16, 2025Insider tradeSEC
4 · Change in ownershipJan 16, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
144 · Notice of proposed saleJan 7, 2025Other filingsSEC
8-K · Current reportDec 9, 2024Current reportSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 18, 2024Big-stake noticeSEC
8-K · Current reportOct 15, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedAug 14, 2024Big-stake noticeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
8-K · Current reportAug 13, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedAug 13, 2024Big-stake noticeSEC
3 · Initial statement of ownershipAug 13, 2024Insider tradeSEC
424B5 · ProspectusAug 12, 2024Offer documentSEC
8-K · Current reportAug 12, 2024ResultsSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportJun 10, 2024Meeting outcomeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
ARS · Annual report to shareholdersApr 25, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2024Meeting noticeSEC
8-K/A · Current report, amendedApr 16, 2024Management or board changeSEC
4 · Change in ownershipApr 8, 2024Insider tradeSEC
10-K · Annual reportMar 15, 2024Annual reportSEC
4 · Change in ownershipMar 14, 2024Insider tradeSEC
8-K · Current reportMar 14, 2024ResultsSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
8-K · Current reportFeb 13, 2024Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
4/A · Change in ownership, amendedJan 18, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
4 · Change in ownershipJan 9, 2024Insider tradeSEC
4 · Change in ownershipJan 9, 2024Insider tradeSEC
4 · Change in ownershipJan 9, 2024Insider tradeSEC

This page holds 200 of 515 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from MeiraGTx Holdings plc’s releases · as of Sep 30, 2026

Common shares
96,042,996
Fully diluted
96,042,996

Fully diluted

LineSharesAs of
Common shares96,042,996Sep 30, 2026

Share count over time

CountShares
Nov 22, 202696,042,996
Sep 30, 202697,619,453

Open Cap table

Shareholders

Institutions

HolderSharesValueChange vs Jun 30Filed
Sanofi12.2MUS$134MNo changeNov 5, 2026
Perceptive Advisors LLC10.8MUS$119MNo changeNov 16, 2026
Rubric Capital Management LP8.43MUS$92.7M−673KNov 16, 2026
Johnson & Johnson6.64MUS$73.1MNo changeOct 26, 2026
BlackRock4.68MUS$51.4M−81,321Nov 13, 2026
Adage Capital Partners Gp, L.L.C.4.45MUS$49M+50,000Nov 16, 2026
Opaleye Management Inc.3.6MUS$39.6M+50,000Nov 16, 2026
Millennium2.73MUS$30.1M−238KNov 16, 2026
683 Capital Management, LLC2.22MUS$24.5M−76,000Nov 16, 2026
Woodline Partners LP1.5MUS$16.5M+382Nov 16, 2026
Show 50 holders
HolderSharesValueChange vs Jun 30Filed
Arrowstreet Capital, Limited Partnership1.48MUS$16.3MNewNov 13, 2026
State Street1.43MUS$15.7M+32,378Nov 12, 2026
Knoll Capital Management, LLC1.25MUS$13.8MNo changeNov 16, 2026
Kennedy Capital Management LLC1.17MUS$12.8M+61,426Nov 13, 2026
Goldman Sachs1.15MUS$12.6M+820KNov 16, 2026
Jacobs Levy Equity Management, Inc1.15MUS$12.6M+131KNov 16, 2026
Long Focus Capital Management, LLC1.08MUS$11.9MNo changeNov 16, 2026
Nuveen944KUS$10.4M+305KNov 10, 2026
Vanguard910KUS$10M+80,330Nov 13, 2026
Geode Capital900KUS$9.9M+51,316Nov 6, 2026
Morgan Stanley856KUS$9.41M−457KNov 13, 2026
Qube Research & Technologies Ltd849KUS$9.33MNewNov 13, 2026
J. Goldman & Co LP846KUS$9.31M+244KNov 16, 2026
Heights Capital Management, Inc823KUS$9.05M−27,494Nov 16, 2026
Mackenzie708KUS$7.79MNewNov 2, 2026
Janus Henderson586KUS$6.45MFirst reportNov 16, 2026
D. E. Shaw & Co., Inc.482KUS$5.3M−371KNov 16, 2026
Globeflex Capital L P459KUS$5.05MNewNov 16, 2026
Panagora Asset Management Inc448KUS$4.93M+97,989Nov 12, 2026
Hennion & Walsh Asset Management, Inc.434KUS$4.77M+11,525Oct 13, 2026
Northern Trust420KUS$4.62M+10,094Nov 16, 2026
Renaissance Technologies416KUS$4.57MNewNov 12, 2026
Erste Asset Management GmbH411KUS$4.58M−280KNov 12, 2026
Lazard Asset Management LLC300KUS$3.3MNewNov 16, 2026
Point72 Asset Management, L.P.283KUS$3.11M+80,295Nov 16, 2026
Bank of America272KUS$2.99M−17,665Nov 16, 2026
Assenagon Asset Management S.A.225KUS$2.48MNewOct 15, 2026
Wellington219KUS$2.41M+75,727Nov 16, 2026
Invesco209KUS$2.3M+115KNov 12, 2026
Privium Fund Management B.V.209KUS$2.29M+12,400Nov 2, 2026
Ghisallo Capital Management LLC200KUS$2.2MNo changeNov 19, 2026
AQR Capital Management LLC191KUS$2.1M−6,017Nov 16, 2026
Alps Advisors Inc172KUS$1.9M+79,107Nov 2, 2026
Susquehanna169KUS$1.86M+121KNov 16, 2026
Man Group plc151KUS$1.66MNewNov 16, 2026
Russell Investments Group, Ltd.151KUS$1.66M+3,236Nov 6, 2026
Schwab145KUS$1.6M+2,921Nov 16, 2026
BNY141KUS$1.55M+2,195Nov 5, 2026
Y-Intercept (Hong Kong) Ltd134KUS$1.47M−14,389Oct 16, 2026
Blair William & Co125KUS$1.38M−78Nov 10, 2026

This page holds 50 of 170 holders. Open Shareholders

Funds

HolderSharesValueChangeAs of
iShares Russell 2000 ETF1.51MUS$20.4M+382KJun 30, 2026
Fidelity Small Cap Index Fund658KUS$7.75M+212KJul 31, 2026
Nuveen Quant Small Cap Equity Fund527KUS$6.21MNewJul 31, 2026
iShares Biotechnology ETF495KUS$6.68M+64,036Jun 30, 2026
Janus Henderson Small Cap Growth Alpha ETF435KUS$5.12MNewJul 31, 2026
iShares Russell 2000 Growth ETF431KUS$5.82M+151KJun 30, 2026
Janus Henderson Small/Mid Cap Growth Alpha ETF314KUS$3.7MNewJul 31, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF260KUS$3.51MNewJun 30, 2026
Vanguard Russell 2000 Index Fund232KUS$2.47M+8,666May 31, 2026
iShares Micro-Cap ETF195KUS$2.63M+80,876Jun 30, 2026
Show 50 holders
HolderSharesValueChangeAs of
Schwab Small-Cap Index Fund145KUS$1.71M+45,228Jul 31, 2026
Vanguard Health Care Index Fund133KUS$1.42M+1,531May 31, 2026
iShares Russell 2000 Value ETF114KUS$1.54M+9,562Jun 30, 2026
Vanguard Strategic Small-Cap Equity Fund113KUS$1.53MNewJun 30, 2026
Master Small Cap Index Series109KUS$1.48M+38,031Jun 30, 2026
BlackRock Advantage Small Cap Growth Fund92,486US$1.25M+25,430Jun 30, 2026
Nuveen Small Cap Blend Index Fund79,737US$940K+27,428Jul 31, 2026
Tax-Managed U.S. Mid & Small Cap Fund79,392US$936KNo changeJul 31, 2026
Nuveen Equity Index Fund77,592US$915KNo changeJul 31, 2026
Nuveen Quant Mid Cap Growth Fund71,980US$849KNewJul 31, 2026
EQ/2000 Managed Volatility Portfolio62,850US$849K+13,231Jun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF57,010US$672K−6,028Jul 31, 2026
AlphaCentric Life Sciences and Healthcare Fund54,469US$736K+775Jun 30, 2026
College Retirement Equities Fund - Total Global Stock Account52,420US$708KNewJun 30, 2026
BlackRock Advantage Small Cap Core Fund51,749US$551KNewMay 29, 2026
PACE Small/Medium Co Growth Equity Investments49,821US$587KNewJul 31, 2026
Fidelity Nasdaq Composite Index Fund49,198US$524K+1,100May 31, 2026
Fidelity Small Cap Growth Index Fund44,617US$603K+19,077Jun 30, 2026
LVIP State Street Small-Cap Index Fund43,092US$582K+12,500Jun 30, 2026
NVIT Multi-Manager Small Company Fund37,558US$507KNewJun 30, 2026
Multi-Manager Small Cap Equity Strategies Fund35,906US$382KNewMay 31, 2026
NVIT Small Cap Value Fund34,550US$467KNewJun 30, 2026
Goldman Sachs Small Cap Equity Insights Fund32,822US$387KNewJul 31, 2026
Virtus Biotech Clinical Trials Etf32,410US$382K+1,468Jul 31, 2026
Vanguard Russell 2000 Growth Index Fund31,787US$339K+940May 31, 2026
EQ/Small Company Index Portfolio31,450US$425KNo changeJun 30, 2026
Small Cap Index Fund30,333US$410K+8,528Jun 30, 2026
Small Company Growth Portfolio29,450US$398KNewJun 30, 2026
Global X Russell 2000 ETF28,718US$339K+8,822Jul 31, 2026
Fidelity MSCI Health Care Index ETF26,392US$311KNewJul 31, 2026
Small Cap Equity Fund24,200US$327KNewJun 30, 2026
Goldman Sachs Small Cap Growth Insights Fund21,977US$259K+15,839Jul 31, 2026
State Street(R) SPDR(R) S&P(R) International Small Cap ETF21,301US$288K+222Jun 30, 2026
MetLife Russell 2000 Index Portfolio20,000US$270K+7,270Jun 30, 2026
Diversified Equity Alpha Master Portfolio19,697US$266KNewJun 30, 2026
North Square Kennedy Microcap Fund19,615US$209K+3,497May 31, 2026
Small Cap Index Fund18,393US$196KNo changeMay 31, 2026
ATM Small Cap Managed Volatility Portfolio18,358US$248K+3,154Jun 30, 2026
EQ/AB Small Cap Growth Portfolio17,720US$239KNo changeJun 30, 2026
Fidelity Small Cap Value Index Fund17,315US$234K+3,550Jun 30, 2026

This page holds 50 of 128 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Forbes Alexandria
Director, Officer: PRESIDENT & CEO
Sale62,000USD 8.45US$524KNov 17, 2026
Giroux Richard
Officer: CFO & COO
Sale56,000USD 9.95US$557KOct 20, 2026
Naylor Stuart
Officer: CHIEF SCI OFCR, OPHTHALMOLOGY
Sale27,659USD 10.64US$294KOct 6, 2026
Forbes Alexandria
Director, Officer: PRESIDENT & CEO
Sale62,000USD 13.86US$859KAug 18, 2026
Giroux Richard
Officer: CFO & COO
Sale56,000USD 12.51US$701KJul 21, 2026
Naylor Stuart
Officer: CHIEF SCI OFCR, OPHTHALMOLOGY
Sale2,547USD 13.86US$35,301Jul 7, 2026
Naylor Stuart
Officer: CHIEF SCI OFCR, OPHTHALMOLOGY
Sale25,112USD 14.90US$374KJul 7, 2026
Forbes Alexandria
Director, Officer: PRESIDENT & CEO
Sale62,000USD 9.17US$569KMay 19, 2026
Giroux Richard
Officer: CFO & COO
Sale56,000USD 10.22US$572KApr 21, 2026
Naylor Stuart
Officer: CHIEF DEV. OFFICER
Sale27,661USD 9.36US$259KApr 7, 2026

Big stakes

HolderStakeSharesDate
Perceptive Advisors LLC12.60%11.7MApr 17, 2026
Rubric Capital Management LP8.77%8.43MSep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Joseph Edelman
Other companies: Kardigan, Inc. (Director · Since at least Jun 17, 2026); Immatics N.V. (Director · Since at least Mar 18, 2026); Solid Biosciences Inc. (Director · Since at least Mar 23, 2021); LeonaBio, Inc. (Director · Since at least Sep 17, 2020); Adagio Medical Holdings, Inc (Director · Jan 22, 2025 – Jan 22, 2025 · Past); Freenome, Inc. (Director · Jun 11, 2024 – Jun 11, 2024 · Past); ARYA Sciences Acquisition Corp V (Director · Jul 12, 2021 – Jul 12, 2021 · Past); ARYA Sciences Acquisition IV Corp (Director · Feb 25, 2021 – Jul 31, 2024 · Past); Landos Biopharma Inc (Director · Feb 3, 2021 – Aug 27, 2021 · Past); Astria Therapeutics Inc (Director · Jan 28, 2021 – Feb 1, 2024 · Past); Nautilus Biotechnology, Inc. (Director · Aug 6, 2020 – Jun 14, 2024 · Past); Cerevel Therapeutics Holdings Inc (Director · Jun 4, 2020 – Feb 20, 2024 · Past); Lyra Therapeutics, Inc. (Director · Apr 30, 2020 – May 31, 2023 · Past); ARYA Sciences Acquisition Corp (Director · Oct 5, 2018 – Oct 5, 2018 · Past)
Director · Since at least Nov 23, 2020
Joel S. Marcus
Other companies: TRex Bio, Inc. (Director · Since at least Oct 13, 2026); Alexandria Real Estate Equities, Inc. (Executive Chairman & Founder · Since at least May 9, 2007); Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Applied Therapeutics Inc (Director · May 13, 2019 – Jun 6, 2024 · Past); Atara Biotherapeutics, Inc. (Director · Oct 15, 2014 – Mar 15, 2019 · Past); Intra-Cellular Therapies Inc (Director · Sep 9, 2013 – Apr 2, 2025 · Past); Rexford Industrial Realty, Inc. (Director · Jul 18, 2013 – May 30, 2014 · Past); PennyMac Mortgage Investment Trust (Director · Aug 4, 2009 – May 16, 2012 · Past)
Director · Jun 8, 2018 – Jun 7, 2022 · Past
Nicole Seligman
Other companies: Praetorian Acquisition Corp. (Director · Since at least Jan 22, 2026); Intuitive Machines, Inc. (Director · Since at least Jun 23, 2023); Far Peak Acquisition Corp (Director · Dec 2, 2020 – Dec 2, 2020 · Past); ViacomCBS Inc (Director · Dec 4, 2019 – May 8, 2024 · Past); Far Point Acquisition Corporation (Director · Jun 11, 2018 – Aug 28, 2020 · Past); Viacom Inc (Director · Aug 18, 2016 – Dec 4, 2019 · Past)
Independent Board Member · Since at least May 9, 2019
Alan Sebulsky
Other companies: Parabilis Medicines, Inc. (President, Apothecary Capital Management, Inc · Since at least Jun 9, 2026); Jazz Pharmaceuticals plc (Director · May 31, 2007 – Mar 9, 2012 · Past); Arrow International Inc (Director · Jan 18, 2006 – Oct 1, 2007 · Past)
Independent Board Member · Since at least Sep 23, 2026
Arnold J Levine
Other companies: PMV Pharmaceuticals, Inc. (Director · Since at least Sep 24, 2020); Applied Biosystems Inc. (Director · Mar 1, 2006 – Nov 21, 2008 · Past); Innoviva, Inc. (Director · Dec 31, 2005 – Mar 21, 2014 · Past)
Director · Jun 8, 2018 – Jun 7, 2022 · Past
Gregory S. Moss
Other companies: Evommune, Inc. (Chief Business and Legal Officer · Since at least Nov 5, 2025); Anteris Technologies Global Corp. (Director · Since at least Jun 7, 2025); Kadmon Holdings Inc (EVP, Gen. Coun. / CCO. · Aug 30, 2019 – Nov 9, 2021 · Past)
Director · Jun 8, 2018 – Jun 8, 2018 · Past
Debra Yu
Other companies: Ascentage Pharma Group International (Independent non-executive Director · Since at least Mar 18, 2026); ARYA Sciences Acquisition Corp V (Director · Jul 12, 2021 – Jul 12, 2021 · Past)
Independent Board Member · Since at least Apr 25, 2022
Robert K Zeldin
Other companies: Immunovant, Inc. (Chief Medical Officer · Dec 18, 2019 – Dec 18, 2019 · Past); Acceleron Pharma Inc (EVP & Chief Medical Officer · Jun 29, 2018 – Jan 25, 2019 · Past)
CHIEF MEDICAL OFFICER · Since at least Aug 3, 2020
Thomas E. Shenk
Other companies: Kadmon Holdings Inc (Director · Jul 26, 2016 – Jun 29, 2017 · Past); Vical Incorporated (Director · Dec 18, 2015 – May 23, 2018 · Past)
Independent Board Member · Since at least Jun 8, 2018
Alexandria Forbes
Other companies: Kadmon Holdings Inc (Director · Jul 26, 2016 – Jun 29, 2017 · Past)
Board Member, President and Chief Executive Officer · Since at least Jun 8, 2018
All 20 people
PersonSeat
Keith R. Harris
Other companies: vTv Therapeutics Inc. (Director · Jul 11, 2022 – Jun 19, 2023 · Past)
Chairman of the Board · Since at least Jun 8, 2018
Richard Giroux
Other companies: Chardan Healthcare Acquisition 2 Corp (Director · Apr 23, 2020 – Apr 23, 2020 · Past)
CFO & COO · Since at least Jun 8, 2018
Bruce GottliebGeneral Counsel · Apr 1, 2019 – Apr 1, 2019 · Past
Ellen HukkelhovenBoard Member · Since at least Jun 8, 2018
Katherine BreedisChief Financial Officer · Oct 2, 2018 – Dec 29, 2018 · Past
Martin IndykDirector · Feb 19, 2019 – Jun 5, 2024 · Past
Neil MendozaDirector · Since at least Jun 8, 2018
Penny Renee FleckCHIEF DEVELOPMENT OFFICER · Since at least May 11, 2026
Robert J WollinGENERAL COUNSEL AND SECRETARY · Since at least Jun 10, 2020
Stuart NaylorCHIEF SCI OFCR, OPHTHALMOLOGY · Since at least Jun 8, 2018

Open People

Log in to ask 6ix AI your own questions about MeiraGTx Holdings plc.